American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

BGNE

BGNE Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

BGNE historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of BGNE by members of U.S. Congress

Politician Type Traded
Daniel S. Goldman House / D Sale $1,001 - $15,000 Jul 12, 2023
Daniel S. Goldman House / D Sale $1,001 - $15,000 Jul 10, 2023
Greg Gianforte House / R Purchase $1,001 - $15,000 Nov 13, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 May 28, 2019
BGNE Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
BGNE Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
BGNE Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in BGNE holdings by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by BGNE's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $350,000 Jul 20, 2026 Issue: Health Issues
  • $250,000 Apr 20, 2026 Issue: Health Issues
  • $230,000 Jan 20, 2026 Issue: Health Issues Accounting
  • $230,000 Oct 20, 2025 Issue: Health Issues
  • $220,000 Jul 21, 2025 Issue: Health Issues
  • $250,000 Apr 21, 2025 Issue: Health Issues
  • $170,000 Jan 24, 2025 Issue: Health Issues
  • $160,000 Oct 20, 2024 Issue: Health Issues
  • $160,000 Jul 22, 2024 Issue: Health Issues
  • $140,000 Jan 22, 2024 Issue: Health Issues
  • $170,000 Oct 20, 2023 Issue: Health Issues
  • $90,000 Apr 20, 2022 Issue: Health Issues
  • $80,000 Jan 20, 2022 Issue: HEALTH ISSUES
  • $80,000 Oct 20, 2021 Issue: HEALTH ISSUES
  • $80,000 Jul 19, 2021 Issue: HEALTH ISSUES
  • $80,000 Apr 20, 2021 Issue: HEALTH ISSUES
  • $80,000 Jan 20, 2021 Issue: None
  • $40,000 Oct 20, 2020 Issue: None
  • $20,000 Jul 20, 2020 Issue: Health Issues
  • $50,000 Apr 17, 2020 Issue: Health Issues
Revolving Door

Former government officials who have lobbied for BGNE

Quiver Logo

No former government officials on record as having lobbied for BGNE

Revolving Door Dashboard
Corporate Lobbying

BGNE Estimated quarterly lobbying spending

Revenue Breakdown

BGNE Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
BGNE Income Statement
BGNE Balance Sheet
BGNE Cash Flow
U.S. Patents

New BGNE patent grants

  • Patent Title: Stable solid dispersion of a b-raf kinase dimer inhibitor, methods of preparation, and uses therefor Mar. 24, 2026
  • Patent Title: Cyclic dinucleotides as sting agonists Oct. 07, 2025
  • Patent Title: Bcl-2 inhibitor Apr. 29, 2025
  • Patent Title: Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist Apr. 22, 2025
  • Patent Title: 3-[(1h-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as hpk1 inhibitor and use thereof Jan. 14, 2025
  • Patent Title: Anti-ox40 antibodies and methods of use Oct. 01, 2024
  • Patent Title: Bcl-2 inhibitors Sep. 03, 2024
  • Patent Title: Imidazo[1,5-a]pyrazine derivatives as pi3kδ inhibitors Feb. 20, 2024
  • Patent Title: Interoperable platform for reducing redundancy in medical database management Jan. 16, 2024
  • Patent Title: Imidazo[1,5-a]pyrazine derivatives as pi3k δ inhibitors Aug. 15, 2023
  • Patent Title: Interoperable platform for reducing redundancy in medical database management Apr. 25, 2023
  • Patent Title: Immunotherapy for hepatocellular carcinoma Mar. 07, 2023
  • Patent Title: Crystalline forms of (s)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof Jan. 17, 2023
  • Patent Title: Anti-pd-l1 antibodies and their use as therapeutics and diagnostics Nov. 29, 2022
  • Patent Title: Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist Oct. 18, 2022
  • Patent Title: Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases Oct. 18, 2022
  • Patent Title: Bcl-2 inhibitors Aug. 23, 2022
  • Patent Title: Interoperable platform for reducing redundancy in medical database management Jul. 19, 2022
  • Patent Title: Btk inhibitors with improved dual selectivity Jul. 05, 2022
  • Patent Title: Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors Jan. 11, 2022
  • Patent Title: Anti-tigit antibodies and their use as therapeutics and diagnostics Jan. 04, 2022
  • Patent Title: Anti-tim-3 antibodies and use thereof Dec. 21, 2021
  • Patent Title: Treatment cancers using a combination comprising parp inhibitors Dec. 21, 2021
  • Patent Title: Imidazo[1,5-a]pyrazine derivatives as pi3k δ inhibitors Oct. 05, 2021
  • Patent Title: Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof Jan. 26, 2021
  • Patent Title: 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases Jan. 05, 2021
  • Patent Title: Combination of a pd-1 antagonist and a raf inhibitor for treating cancer Dec. 15, 2020
  • Patent Title: 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases May. 12, 2020
  • Patent Title: Fused tricyclic compounds as raf kinase inhibitors Mar. 03, 2020
  • Patent Title: Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Feb. 18, 2020
  • Patent Title: Anti-pd-l1 antibodies and their use as therapeutics and diagnostics Jan. 28, 2020
  • Patent Title: Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors Dec. 10, 2019
  • Patent Title: Process for preparing a parp inhibitor, crystalline forms, and uses thereof Oct. 29, 2019
  • Patent Title: Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore Jul. 16, 2019
  • Patent Title: 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases May. 07, 2019
  • Patent Title: Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Mar. 20, 2018
  • Patent Title: Fused tricyclic compounds as raf kinase inhibitors Feb. 20, 2018
  • Patent Title: Anti-pd1 antibodies and their use as therapeutics and diagnostics Dec. 05, 2017
  • Patent Title: Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones Nov. 28, 2017
  • Patent Title: Fused tricyclic amide compounds as multiple kinase inhibitors Jun. 06, 2017
  • Patent Title: Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Jun. 06, 2017
  • Patent Title: Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors Apr. 11, 2017
  • Patent Title: Substituted imidazo[1,2-b]pyrazoles as bruton's tyrosine kinase modulators Jan. 31, 2017
  • Patent Title: Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators Sep. 20, 2016
  • Patent Title: Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones Jul. 19, 2016
  • Patent Title: Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as parp inhibitors May. 03, 2016
  • Patent Title: Fused tricyclic compounds as raf kinase inhibitors Mar. 01, 2016
  • Patent Title: Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors Feb. 16, 2016
  • Patent Title: Anti-pd1 antibodies and their use as therapeutics and diagnostics Dec. 22, 2015
  • Patent Title: Anti-pd1 antibodies and their use as therapeutics and diagnostics May. 27, 2014
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to BGNE from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
BGNE News

Recent insights relating to BGNE

CNBC Recommendations

Recent picks made for BGNE stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BGNE

BGNE Analyst Ratings

BGNE Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
BGNE Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $BGNE stock a Buy, Sell, or Hold?

  • What is the price target for $BGNE stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

BGNE Top Shareholders
Shareholder
Shares Held
BGNE Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $BGNE stock?

  • Who owns the most shares of $BGNE stock?

  • What funds own $BGNE stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

BGNE Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view BGNE Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About BGNE

No description available

BGNE (BGNE) Historical Stock Prices

BGNE (BGNE) closed at $184.71 on December 31, 2024. Over the past year its adjusted close ranged from $129.52 to $246.04. Daily prices go back to February 3, 2016, 2,243 trading days in all.

  • 1 month-14.09%
  • 3 months-20.03%
  • Year to date+2.41%
  • 1 year+2.41%
  • 3 years-31.82%
  • 5 years+11.32%
  • Max+552.22%
See every congressional and insider trade on the BGNE price chart

Quiver Premium charts BGNE's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Dec 31, 2024 184.00 187.42 183.91 184.71 184.71 331,631
Dec 30, 2024 180.08 185.24 179.73 183.81 183.81 178,913
Dec 27, 2024 181.81 184.91 180.26 181.89 181.89 169,767
Dec 26, 2024 181.58 184.98 180.99 184.68 184.68 163,887
Dec 24, 2024 177.72 182.33 177.09 181.62 181.62 148,370
Dec 23, 2024 178.63 179.93 176.57 177.70 177.70 231,186
Dec 20, 2024 176.29 179.25 175.80 176.50 176.50 368,466
Dec 19, 2024 175.18 177.30 170.99 174.72 174.72 296,091
Dec 18, 2024 177.56 178.69 174.51 175.87 175.87 592,487
Dec 17, 2024 178.00 179.59 176.06 179.06 179.06 366,173
Dec 16, 2024 177.69 180.00 174.50 176.33 176.33 538,230
Dec 13, 2024 177.15 179.65 176.15 179.35 179.35 368,615
Dec 12, 2024 184.02 186.35 179.69 180.27 180.27 387,828
Dec 11, 2024 186.92 187.64 183.26 184.38 184.38 491,546
Dec 10, 2024 195.52 196.96 183.29 187.50 187.50 1,260,783
Dec 9, 2024 209.10 211.00 203.59 207.62 207.62 513,042
Dec 6, 2024 207.72 209.46 204.09 205.62 205.62 348,989
Dec 5, 2024 204.47 204.99 200.00 201.66 201.66 254,671
Dec 4, 2024 203.37 206.43 198.70 199.09 199.09 339,750
Dec 3, 2024 206.22 208.23 202.63 206.01 206.01 395,221
Dec 2, 2024 214.89 216.73 200.00 205.75 205.75 2,095,602
Nov 29, 2024 215.13 216.37 211.37 215.00 215.00 258,633
Nov 27, 2024 201.31 210.62 201.03 206.16 206.16 341,342
Nov 26, 2024 190.20 192.17 186.52 192.11 192.11 308,162
Nov 25, 2024 192.03 194.98 188.14 190.30 190.30 276,415
Nov 22, 2024 190.94 192.90 189.01 190.51 190.51 222,704
Nov 21, 2024 196.09 197.48 191.41 194.56 194.56 221,472
Nov 20, 2024 195.00 198.48 192.00 194.26 194.26 344,281
Nov 19, 2024 188.24 190.09 187.19 187.77 187.77 238,525
Nov 18, 2024 186.92 188.32 184.49 187.69 187.69 444,597
Nov 15, 2024 187.79 191.45 186.16 189.23 189.23 273,933
Nov 14, 2024 193.58 195.64 191.25 193.29 193.29 213,477
Nov 13, 2024 197.44 200.88 193.28 195.45 195.45 281,526
Nov 12, 2024 198.00 203.00 189.60 193.64 193.64 335,253
Nov 11, 2024 206.37 209.29 204.40 205.04 205.04 334,489
Nov 8, 2024 203.84 206.35 202.59 205.47 205.47 207,402
Nov 7, 2024 202.73 208.06 202.73 206.82 206.82 144,300
Nov 6, 2024 208.03 208.03 196.15 202.73 202.73 551,774
Nov 5, 2024 208.13 209.99 205.62 208.03 208.03 322,583
Nov 4, 2024 204.86 210.53 204.86 207.25 207.25 177,228
Nov 1, 2024 206.63 209.05 202.90 204.21 204.21 463,006
Oct 31, 2024 205.50 205.99 202.19 202.64 202.64 216,786
Oct 30, 2024 213.88 213.88 205.32 205.99 205.99 898,445
Oct 29, 2024 217.00 219.57 214.80 216.53 216.53 229,354
Oct 28, 2024 215.11 219.03 214.30 217.22 217.22 142,696
Oct 25, 2024 213.18 215.26 211.30 212.81 212.81 245,775
Oct 24, 2024 214.75 221.60 213.62 214.15 214.15 157,964
Oct 23, 2024 223.88 224.00 218.82 221.01 221.01 145,157
Oct 22, 2024 219.14 221.12 218.45 220.63 220.63 107,826
Oct 21, 2024 220.00 221.84 217.31 219.92 219.92 187,949
Oct 18, 2024 222.35 222.35 215.12 218.97 218.97 528,238
Oct 17, 2024 219.40 220.66 211.56 212.39 212.39 397,095
Oct 16, 2024 224.26 224.26 220.85 222.16 222.16 164,319
Oct 15, 2024 223.43 225.76 221.16 222.60 222.60 276,881
Oct 14, 2024 228.73 231.46 221.50 227.05 227.05 574,516
Oct 11, 2024 234.33 237.68 233.49 236.10 236.10 373,632
Oct 10, 2024 240.38 243.83 237.50 239.38 239.38 309,073
Oct 9, 2024 241.10 246.55 234.86 240.40 240.40 700,020
Oct 8, 2024 229.00 239.01 225.39 235.43 235.43 521,860
Oct 7, 2024 247.00 247.50 239.86 243.02 243.02 594,184
Oct 4, 2024 247.00 248.16 243.06 246.04 246.04 607,526
Oct 3, 2024 233.50 237.94 232.78 233.64 233.64 303,298
Oct 2, 2024 236.24 238.80 227.43 233.60 233.60 410,278
Oct 1, 2024 222.96 231.34 221.03 230.98 230.98 333,290
Sep 30, 2024 237.10 237.10 218.00 224.51 224.51 496,839
Sep 27, 2024 218.89 223.96 217.71 218.42 218.42 394,253
Sep 26, 2024 212.00 213.77 208.32 212.53 212.53 242,138
Sep 25, 2024 206.73 210.51 206.31 206.72 206.72 178,085
Sep 24, 2024 204.55 210.76 203.51 209.31 209.31 312,081
Sep 23, 2024 200.75 203.30 200.12 201.31 201.31 189,938
Sep 20, 2024 205.67 208.28 200.98 201.99 201.99 411,783
Sep 19, 2024 198.00 200.98 197.73 198.59 198.59 194,614
Sep 18, 2024 198.72 199.99 197.00 197.28 197.28 187,755
Sep 17, 2024 199.05 200.69 196.62 197.51 197.51 103,863
Sep 16, 2024 196.43 197.53 194.07 196.45 196.45 204,525
Sep 13, 2024 200.00 200.61 195.71 198.49 198.49 212,446
Sep 12, 2024 199.00 200.75 194.11 196.27 196.27 483,661
Sep 11, 2024 206.62 215.00 205.60 211.15 211.15 602,657
Sep 10, 2024 191.76 198.53 191.73 197.70 197.70 182,742
Sep 9, 2024 189.67 193.47 189.21 193.31 193.31 144,720
Sep 6, 2024 192.81 193.03 188.51 191.32 191.32 136,979
Sep 5, 2024 190.21 194.57 190.21 191.58 191.58 178,182
Sep 4, 2024 187.09 191.20 186.03 188.65 188.65 516,226
Sep 3, 2024 190.03 192.98 187.68 188.26 188.26 364,414
Aug 30, 2024 196.02 196.37 190.74 191.78 191.78 293,438
Aug 29, 2024 197.85 199.65 196.75 198.50 198.50 135,710
Aug 28, 2024 200.91 201.56 196.00 198.16 198.16 163,599
Aug 27, 2024 200.02 202.59 199.75 202.17 202.17 313,595
Aug 26, 2024 199.64 201.28 197.68 199.22 199.22 429,048
Aug 23, 2024 194.39 196.32 191.11 193.82 193.82 207,855
Aug 22, 2024 199.00 199.00 195.36 195.63 195.63 254,755
Aug 21, 2024 196.00 199.00 195.63 197.98 197.98 336,398
Aug 20, 2024 194.19 195.98 192.84 194.21 194.21 281,077
Aug 19, 2024 192.74 193.30 189.98 192.50 192.50 266,328
Aug 16, 2024 194.23 197.99 194.07 194.66 194.66 376,468
Aug 15, 2024 190.00 192.48 187.45 190.89 190.89 277,976
Aug 14, 2024 185.66 190.92 185.00 186.70 186.70 307,232
Aug 13, 2024 188.13 191.50 186.03 187.20 187.20 319,582
Aug 12, 2024 185.00 190.72 183.41 190.03 190.03 453,770
Aug 9, 2024 180.49 184.65 178.92 182.76 182.76 317,453
Aug 8, 2024 178.80 185.66 176.98 183.03 183.03 607,835
Aug 7, 2024 180.00 182.28 170.36 176.73 176.73 682,887
Aug 6, 2024 167.00 175.61 166.55 171.32 171.32 285,213
Aug 5, 2024 161.01 168.00 158.84 165.66 165.66 302,192
Aug 2, 2024 160.03 164.94 155.75 163.23 163.23 177,981
Aug 1, 2024 164.85 167.75 161.46 162.29 162.29 326,455
Jul 31, 2024 163.49 168.98 162.90 166.58 166.58 291,687
Jul 30, 2024 161.51 161.51 156.71 156.98 156.98 156,361
Jul 29, 2024 159.72 161.98 159.00 160.94 160.94 120,521
Jul 26, 2024 163.82 165.50 161.70 162.54 162.54 101,487
Jul 25, 2024 160.92 164.61 158.35 163.27 163.27 257,969
Jul 24, 2024 157.00 163.93 154.43 163.56 163.56 296,360
Jul 23, 2024 155.00 158.03 153.77 157.53 157.53 263,471
Jul 22, 2024 156.12 161.24 155.30 160.93 160.93 127,735
Jul 19, 2024 153.53 155.77 152.81 154.74 154.74 119,067
Jul 18, 2024 150.74 155.01 148.81 152.03 152.03 240,127
Jul 17, 2024 151.28 156.77 150.31 153.64 153.64 304,369
Jul 16, 2024 150.50 154.97 146.87 152.92 152.92 422,954
Jul 15, 2024 150.19 151.22 146.21 147.76 147.76 287,598
Jul 12, 2024 154.69 158.99 151.92 152.17 152.17 378,036
Jul 11, 2024 148.01 152.67 147.14 150.50 150.50 250,875
Jul 10, 2024 143.71 147.90 143.29 146.04 146.04 187,543
Jul 9, 2024 144.38 146.20 143.00 144.53 144.53 637,097
Jul 8, 2024 142.11 148.99 142.00 144.35 144.35 334,757
Jul 5, 2024 149.00 149.00 145.53 147.04 147.04 88,432
Jul 3, 2024 146.74 148.35 145.27 147.98 147.98 91,322
Jul 2, 2024 143.04 145.69 142.80 143.93 143.93 243,959
Jul 1, 2024 144.30 148.94 143.40 144.89 144.89 153,790
Jun 28, 2024 144.69 145.00 141.84 142.67 142.67 318,147
Jun 27, 2024 142.27 148.00 141.31 145.58 145.58 276,015
Jun 26, 2024 150.22 150.68 146.00 146.44 146.44 233,169
Jun 25, 2024 155.95 155.95 150.93 150.99 150.99 332,871
Jun 24, 2024 156.31 162.39 155.34 159.15 159.15 139,936
Jun 21, 2024 153.45 158.57 150.88 156.11 156.11 217,941
Jun 20, 2024 153.62 156.00 152.00 155.54 155.54 129,240
Jun 18, 2024 158.39 159.47 152.71 154.70 154.70 170,761
Jun 17, 2024 165.29 165.29 158.11 159.38 159.38 97,166
Jun 14, 2024 163.87 163.99 160.64 162.58 162.58 174,057
Jun 13, 2024 167.00 168.80 163.43 166.38 166.38 314,022
Jun 12, 2024 157.75 169.17 156.50 168.11 168.11 401,710
Jun 11, 2024 155.02 158.69 151.69 158.59 158.59 151,711
Jun 10, 2024 155.14 157.84 154.58 156.07 156.07 78,315
Jun 7, 2024 157.60 159.37 156.09 156.36 156.36 79,617
Jun 6, 2024 157.81 159.91 156.50 157.60 157.60 84,336
Jun 5, 2024 157.27 159.18 156.80 159.03 159.03 101,640
Jun 4, 2024 148.99 155.38 148.03 155.09 155.09 175,084
Jun 3, 2024 148.50 150.94 144.66 146.24 146.24 271,393
May 31, 2024 150.00 155.06 146.94 148.85 148.85 287,022
May 30, 2024 151.28 155.87 151.28 154.25 154.25 208,503
May 29, 2024 149.36 152.12 147.03 151.28 151.28 73,381
May 28, 2024 152.78 154.39 151.45 153.11 153.11 119,851
May 24, 2024 154.38 156.35 152.02 152.71 152.71 144,597
May 23, 2024 162.80 164.13 155.52 156.17 156.17 153,928
May 22, 2024 169.26 171.83 166.87 167.92 167.92 102,681
May 21, 2024 167.91 171.63 167.37 167.39 167.39 91,683
May 20, 2024 172.83 175.66 171.81 174.32 174.32 127,705
May 17, 2024 171.00 176.00 169.76 172.85 172.85 275,361
May 16, 2024 168.23 172.30 167.56 171.03 171.03 256,229
May 15, 2024 162.54 165.27 159.71 164.88 164.88 133,253
May 14, 2024 161.75 163.72 159.90 160.77 160.77 115,859
May 13, 2024 160.96 164.17 160.96 162.17 162.17 108,508
May 10, 2024 166.30 166.30 161.00 161.13 161.13 196,397
May 9, 2024 166.06 169.38 165.65 168.64 168.64 255,961
May 8, 2024 165.49 168.46 161.38 164.44 164.44 221,000
May 7, 2024 162.99 164.40 158.21 160.56 160.56 111,912
May 6, 2024 164.51 165.00 161.94 162.48 162.48 160,154
May 3, 2024 162.51 162.51 159.25 162.25 162.25 195,009
May 2, 2024 160.99 164.60 158.81 162.01 162.01 268,400
May 1, 2024 154.30 157.89 154.30 156.53 156.53 176,901
Apr 30, 2024 155.00 156.64 150.29 153.94 153.94 205,282
Apr 29, 2024 155.00 157.89 153.08 156.53 156.53 185,728
Apr 26, 2024 152.11 154.47 150.73 153.58 153.58 208,460
Apr 25, 2024 148.40 152.83 146.16 148.56 148.56 409,342
Apr 24, 2024 143.45 146.22 141.78 144.12 144.12 215,690
Apr 23, 2024 135.75 142.22 134.68 138.99 138.99 203,615
Apr 22, 2024 130.55 133.09 129.96 130.94 130.94 152,563
Apr 19, 2024 130.00 130.85 126.97 129.52 129.52 296,412
Apr 18, 2024 131.40 136.00 131.40 131.96 131.96 125,955
Apr 17, 2024 134.40 134.40 131.28 131.86 131.86 200,058
Apr 16, 2024 137.28 137.71 133.71 134.05 134.05 308,982
Apr 15, 2024 140.68 142.63 137.38 138.40 138.40 228,159
Apr 12, 2024 145.00 146.81 140.08 141.30 141.30 139,454
Apr 11, 2024 147.62 148.93 145.34 146.13 146.13 243,171
Apr 10, 2024 150.34 150.97 147.97 149.76 149.76 272,924
Apr 9, 2024 153.70 155.37 150.84 154.02 154.02 115,201
Apr 8, 2024 148.84 151.52 148.50 149.75 149.75 109,180
Apr 5, 2024 149.57 151.44 148.00 150.03 150.03 90,661
Apr 4, 2024 153.26 153.28 149.30 149.57 149.57 81,654
Apr 3, 2024 153.53 154.12 150.79 151.95 151.95 56,991
Apr 2, 2024 155.51 157.32 152.69 153.25 153.25 84,095
Apr 1, 2024 156.87 159.34 152.77 159.23 159.23 126,964
Mar 28, 2024 157.00 157.38 155.09 156.39 156.39 104,129
Mar 27, 2024 153.05 155.91 153.05 155.08 155.08 76,134
Mar 26, 2024 155.96 155.99 151.49 153.81 153.81 104,417
Mar 25, 2024 153.14 155.63 151.94 153.92 153.92 122,678
Mar 22, 2024 156.48 158.10 151.85 152.02 152.02 445,487
Mar 21, 2024 167.10 167.84 162.50 163.70 163.70 192,989
Mar 20, 2024 169.44 170.36 166.66 169.62 169.62 195,654
Mar 19, 2024 168.31 171.25 165.83 168.10 168.10 145,070
Mar 18, 2024 168.33 170.78 168.33 168.50 168.50 154,842
Mar 15, 2024 171.79 171.79 166.90 170.00 170.00 350,215
Mar 14, 2024 174.14 174.79 165.40 168.90 168.90 395,199
Mar 13, 2024 180.98 184.80 175.49 176.47 176.47 551,352
Mar 12, 2024 168.70 170.00 162.26 163.75 163.75 188,675
Mar 11, 2024 161.79 167.64 158.72 164.53 164.53 126,937
Mar 8, 2024 163.80 166.07 157.39 158.52 158.52 188,440
Mar 7, 2024 158.04 163.10 158.04 162.25 162.25 138,994
Mar 6, 2024 161.28 162.02 158.79 159.52 159.52 212,634
Mar 5, 2024 163.81 164.66 159.78 160.42 160.42 164,854
Mar 4, 2024 164.26 169.03 160.59 167.86 167.86 183,199
Mar 1, 2024 163.81 168.11 161.60 165.02 165.02 190,688
Feb 29, 2024 176.05 176.05 165.58 165.65 165.65 281,679
Feb 28, 2024 173.51 179.11 173.51 178.48 178.48 602,580
Feb 27, 2024 164.95 179.88 164.07 179.69 179.69 511,302
Feb 26, 2024 159.14 162.11 154.76 160.26 160.26 579,096
Feb 23, 2024 155.22 158.47 154.38 155.10 155.10 217,784
Feb 22, 2024 152.93 155.51 151.64 153.78 153.78 194,572
Feb 21, 2024 149.02 151.85 148.61 150.80 150.80 180,908
Feb 20, 2024 149.55 150.90 147.06 148.05 148.05 138,225
Feb 16, 2024 148.90 149.50 146.21 148.23 148.23 135,075
Feb 15, 2024 146.75 149.34 145.01 146.07 146.07 184,301
Feb 14, 2024 145.85 147.64 143.50 145.87 145.87 285,727
Feb 13, 2024 144.00 146.36 141.34 141.80 141.80 190,910
Feb 12, 2024 147.65 149.72 145.88 146.57 146.57 138,052
Feb 9, 2024 144.61 147.18 143.01 146.98 146.98 147,319
Feb 8, 2024 145.00 145.89 141.54 142.88 142.88 237,902
Feb 7, 2024 148.16 150.43 146.89 147.76 147.76 277,447
Feb 6, 2024 149.88 155.47 146.51 153.58 153.58 324,378
Feb 5, 2024 145.26 146.28 139.73 141.81 141.81 425,421
Feb 2, 2024 140.41 147.21 132.95 144.48 144.48 736,231
Feb 1, 2024 152.63 152.63 149.88 149.93 149.93 291,296
Jan 31, 2024 152.80 153.19 147.88 148.23 148.23 402,337
Jan 30, 2024 158.80 158.80 153.94 155.04 155.04 384,487
Jan 29, 2024 161.62 162.95 155.23 162.08 162.08 366,143
Jan 26, 2024 157.98 163.18 157.61 161.90 161.90 555,661
Jan 25, 2024 161.37 166.15 159.60 165.00 165.00 330,129
Jan 24, 2024 164.00 166.34 160.54 160.70 160.70 251,252
Jan 23, 2024 157.54 162.50 156.86 162.27 162.27 349,150
Jan 22, 2024 157.10 158.04 153.13 156.62 156.62 360,408
Jan 19, 2024 160.50 160.50 157.97 159.78 159.78 441,807
Jan 18, 2024 168.85 168.85 164.40 165.35 165.35 302,826
Jan 17, 2024 165.01 167.80 163.85 167.80 167.80 443,492
Jan 16, 2024 174.17 175.00 171.66 173.25 173.25 295,776
Jan 12, 2024 173.49 177.44 173.01 175.21 175.21 172,617
Jan 11, 2024 173.72 176.00 171.62 175.10 175.10 154,921
Jan 10, 2024 183.00 184.52 172.03 175.05 175.05 384,558
Jan 9, 2024 171.00 182.29 171.00 181.47 181.47 276,056
Jan 8, 2024 165.98 172.03 163.55 171.54 171.54 236,227
Jan 5, 2024 167.28 170.26 165.13 165.38 165.38 363,392
Jan 4, 2024 181.80 181.84 174.09 175.70 175.70 269,065
Jan 3, 2024 174.56 182.52 172.50 181.43 181.43 304,469
Jan 2, 2024 176.05 177.09 172.50 177.00 177.00 331,946

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
BGNE Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at BGNE, per a recent SEC DEF 14A filing.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation